 |
|
|
|
 |
|
|
| Article 1 to 10 out of 36 concerning Novozymes A/S
|
-
Novozymes and Prometic enter into alliance for purification of albumin-fusion proteins
(04 Feb 2010)
Novozymes and ProMetic Life Sciences Inc. announced that they have entered into a strategic alliance regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic’s UK subsidiary, ...
-
Novozymes Biopharma secures CPhI 2009 innovation award for its albufuse technology
(03 Nov 2009)
Novozymes Biopharma, part of Novozymes A/S, has claimed the Bronze Innovation Award at the CPhI Worldwide 2009 in Madrid, Spain, for its albumin fusion technology, albufuse. The CPhI Innovation Awards are designed to reward organizations that play ...
-
Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
(11 May 2009)
Human Genome Sciences, Inc. and Novozymes Biopharma, a part of Novozymes, announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology.Under the amended ...
-
Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid
(29 Apr 2009)
Novozymes Biopharma, part of Novozymes announced the construction of a new cGMP facility at the company's existing site in Tianjin, China that will enable its novel form of Bacillus-based Hyaluronic Acid (bHA), HyaCare, to be used within the ...
-
Novozymes Biopharma Signs License Agreement with GE Healthcare to Produce and Sell Protein A
(11 Mar 2009)
Novozymes Biopharma UK Ltd., part of Novozymes, announced a newly signed license agreement with GE Healthcare Life Sciences. This license enables Novozymes Biopharma to produce and deliver native, animal-free protein A using GE Healthcare ...
-
Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology
(20 Feb 2009)
Novozymes Biopharma and Upperton Limited announced that the European Patent Office has confirmed the official Decision to Grant a European patent for their targeted drug delivery joint patent application (European patent No 1605979). The decision ...
-
Novozymes Awarded USD 12.3 Million Contract From the U.S. Department of Energy
(10 Oct 2008)
Funding Will Be Used to Further Increase Efficiency of Enzymes for Converting Waste Biomass to Cellulosic Ethanol
Novozymes was awarded a USD 12.3 million contract from the U.S. Department of Energy (DoE) to improve the enzymes necessary to produce cellulosic ethanol. Novozymes’ project DECREASE (Development of a Commercial-Ready Enzyme Application System for ...
-
Gene Bridges licenses Red/ET Recombineering to Novozymes
(23 Apr 2008)
Gene Bridges GmbH announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to ...
-
Cargill and Novozymes to enable production of acrylic acid via HPA from renewable raw materials
(16 Jan 2008)
Cargill and Novozymes announced a joint agreement to develop technology enabling the production of acrylic acid via 3-hydroxypropionic acid (3HPA) from renewable raw materials. The project is supported by a $1.5 million matching cooperative ...
-
Novozymes closes streptococcal based production of hyaluronic acid
(09 Jan 2008)
Novozymes has decided to close its production facility in the Shandong Province, China, by January 7, 2008. As a result of the closure, Novozymes will no longer produce or sell streptococcal based hyaluronic acid but maintain its focus on bacillus ...
Additional information
Novozymes A/S
Bagsvaerd, Denmark
Company
|
|
|
|
|
|
Top
